Profilo committente
Iris-achats
BE- Aggiudicazioni
- 8
- Valore totale aggiudicato
- —
- Paesi
- Belgio
- Ultima aggiudicazione
- 12 gen 2024
- In scadenza entro 12 mesi
- 0
Storico delle aggiudicazioni
| Data | Fornitore | Titolo | Categoria | Importo | Paese | Scadenza | Fonte |
|---|---|---|---|---|---|---|---|
| 12/01/2024 | GE HEALTHCARE | Belgium – Ultrasonic unit – Echografie-scanners voor verschillende medische disciplines | — | — | BE | — | Vedi su TED ↗ |
| 26/12/2023 | GE HEALTHCARE | Belgium – Imaging equipment for medical, dental and veterinary use – Levering, ingebruikname en onderhoud van een mammografie-unit en een mini-chirurgische C-boog | — | — | BE | — | Vedi su TED ↗ |
| 26/12/2023 | GE HEALTHCARE | Belgium – Ultrasonic unit – Echografie-scanners voor verschillende medische disciplines | — | — | BE | — | Vedi su TED ↗ |
| 08/12/2023 | Canon Medical Systems Belgium SA | Belgium – Imaging equipment for medical, dental and veterinary use – Levering, ingebruikname en onderhoud van een mammografie-unit en een mini-chirurgische C-boog | — | — | BE | — | Vedi su TED ↗ |
| 08/12/2023 | GE HEALTHCARE | Belgium – Ultrasonic unit – Echografie-scanners voor verschillende medische disciplines | — | — | BE | — | Vedi su TED ↗ |
| 04/12/2023 | GE HEALTHCARE | Belgium – Ultrasonic unit – Echografie-scanners voor verschillende medische disciplines | — | — | BE | — | Vedi su TED ↗ |
| 20/10/2023 | NOVARTIS PHARMA NV | Belgium – Pharmaceutical products – Everolimus farmaceutische specialiteiten, erenumab, indacaterol/mometason, secukinumab, deferoxamine (mesilaat), indacaterol/glycopyrronium (bromide)/mometason, sacubitril/valsartan, vildagliptine/metformine (hydrochloride), vildagliptine, canakinumab, ruxolitinib (fosfaat), ribociclib, ranibizumab, siponimod, trametinib (dimethylsulfoxide), methylergometrine (maleaat), … | — | — | BE | — | Vedi su TED ↗ |
| 16/10/2023 | Belgium – Pharmaceutical products – Farmaceutische specialiteiten op basis van paliperidon (palmitaat), risperidon, etravirine, rilpivirine (hydrochloride), ustekinumab, decitabine, darunavir (ethanolaat)/cobicistat, ibrutinib, guselkumab, daratumumab, selexipag, esketamine en apalutamide | — | — | BE | — | Vedi su TED ↗ |